Julie Barber

Julie Barber

Auto-generated profile, based on publicly available information

Julie Barber

Department of Statistical Science, University College London, London WC1E 6BT, UK

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2000 in BMJ
Verified
Journal Article
Closed access
PDF file
STSimon G Thompson
Simon G Thompson
JBJulie A Barber
Julie A Barber

27 November 2000 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
JBJulie A. Barber
Julie A. Barber
STSimon G. Thompson
Simon G. Thompson

1 February 2000 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ASA.J. Swerdlow
A.J. Swerdlow
JBJ.A. Barber
J.A. Barber
GHG. Vaughan Hudson
G. Vaughan Hudson
DCDavid Cunningham
David Cunningham
RGR.K. Gupta
R.K. Gupta
DLD.C. Linch
D.C. Linch
PURPOSE: To assess long-term site-specific risks of second malignancy after Hodgkin’s disease in relation to age at treatment and other factors. PATIENTS AND METHODS: A cohort of 5,519 British patients with Hodgkin’s disease treated during 1963 through 1993 was assembled and followed-up for second malignancy and mortality. Follow-up was 97% complete. RESULTS: Three hundred twenty-two second malignancies occurred. Relative risks of gastrointestinal, lung, breast, and bone and soft tissue cancers, and of leukemia, increased significantly with younger age at first treatment. Absolute excess risks and cumulative risks of solid cancers and leukemia, however, were greater at older ages than at younger ages. Gastrointestinal cancer risk was greatest after mixed-modality treatment (relative risk [RR] = 3.3; 95% confidence interval [CI], 2.1 to 4.8); lung cancer risks were significantly increased after chemotherapy (RR = 3.3; 95% CI, 2.4 to 4.7), mixed-modality treatment (RR = 4.3; 95% CI, 2.9 to 6.2), and radiotherapy (RR = 2.9; 95% CI, 1.9 to 4.1); breast cancer risk was increased only after radiotherapy without chemotherapy (RR = 2.5; 95% CI, 1.4 to 4.0); and leukemia risk was significantly increased after chemotherapy (RR = 31.6; 95% CI, 19.7 to 47.6) and mixed-modality treatment (RR = 38.1; 95% CI, 24.6 to 55.9). These risks were generally greater after treatment at younger ages: for patients treated at ages younger than 25 years, there were RRs of 18.7 (95% CI, 5.8 to 43.5) for gastrointestinal cancer after mixed-modality treatment, 14.4 (95% CI, 5.7 to 29.3) for breast cancer after radiotherapy, and 85.2 (95% CI, 45.3 to 145.7) for leukemia after chemotherapy (with or without radiotherapy). CONCLUSION: Age at treatment has a major effect on risk of second malignancy after Hodgkin’s disease. Although absolute excess risks are greater for older patients, RRs of several important malignancies are much greater for patients who are treated when young. The increased risk of gastrointestinal cancers may relate particularly to mixed-modality treatment, and that of lung cancer to chemotherapy as well as radiotherapy; there are also well-known increased risks of breast cancer from radiotherapy and leukemia from chemotherapy. The roles of specific chemotherapeutic agents in the etiology of solid cancers after Hodgkin’s disease require detailed investigation.

2 October 2004 in Journal of Health Services Research & Policy
Verified
Journal Article
Closed access
JBJulie Barber
Julie Barber
STSimon Thompson
Simon Thompson
Objective: Choosing an appropriate method for regression analyses of cost data is problematic because it must focus on population means while taking into account the typically skewed distribution of the data. In this paper we illustrate the use of generalised linear models for regression analysis of cost data. Methods: We consider generalised linear models with either an identity link function (providing additive covariate effects) or log link function (providing multiplicative effects), and with gaussian (normal), overdispersed poisson, gamma, or inverse gaussian distributions. These are applied to estimate the treatment effects in two randomised trials adjusted for baseline covariates. Criteria for choosing an appropriate model are presented. Results: In both examples considered, the gaussian model fits poorly and other distributions are to be preferred. When there are variables of prognostic importance in the model, using different distributions can materially affect the estimates obtained; it may also be possible to discriminate between additive and multiplicative covariate effects. Conclusions: Generalised linear models are attractive for the regression of cost data because they provide parametric methods of analysis where a variety of non-normal distributions can be specified and the way covariates act can be altered. Unlike the use of data transformation in ordinary least-squares regression, generalised linear models make inferences about the mean cost directly.

31 July 1999 in BMJ
Verified
Journal Article
Closed access
PDF file
JMJennifer Klaber Moffett
Jennifer Klaber Moffett
DTDavid Torgerson
David Torgerson
SBSally Bell-Syer
Sally Bell-Syer
DJDavid Jackson
David Jackson
HLHugh Llewlyn-Phillips
Hugh Llewlyn-Phillips
JBJulie Barber
Julie Barber
Objective: To evaluate effectiveness of an exercise programme in a community setting for patients with low back pain to encourage a return to normal activities. Design: Randomised controlled trial of progressive exercise programme compared with usual primary care management. Patients' preferences for type of management were elicited independently of randomisation. Participants: 187 patients aged 18-60 years with mechanical low back pain of 4 weeks to 6 months' duration. Interventions: Exercise classes led by a physiotherapist that included strengthening exercises for all main muscle groups, stretching exercises, relaxation session, and brief education on back care. A cognitive-behavioural approach was used. Main outcome measures: Assessments of debilitating effects of back pain before and after intervention and at 6 months and 1 year later. Measures included Roland disability questionnaire, Aberdeen back pain scale, pain diaries, and use of healthcare services. Results: At 6 weeks after randomisation, the intervention group improved marginally more than the control group on the disability questionnaire and reported less distressing pain. At 6 months and 1 year, the intervention group showed significantly greater improvement in the disability questionnaire score (mean difference in changes 1.35, 95% confidence interval 0.13 to 2.57). At 1 year, the intervention group also showed significantly greater improvement in the Aberdeen back pain scale (4.44, 1.01 to 7.87) and reported only 378 days off work compared with 607 in the control group. The intervention group used fewer healthcare resources. Outcome was not influenced by patients' preferences. Conclusions: The exercise class was more clinically effective than traditional general practitioner management, regardless of patient preference, and was cost effective. Patients with back pain need to return to normal activities as soon as possible but are often afraid that movement or activity may be harmful An exercise programme led by a physiotherapist in the community and based on cognitive-behavioural principles helped patients to cope better with their pain and function better even one year later Patients' preferences for type of management did not affect outcome Patients in the intervention group tended to use fewer healthcare resources and took fewer days off work This type of exercise programme should be more widely available

31 October 1998 in BMJ
Verified
Journal Article
Closed access
PDF file
JBJulie A Barber
Julie A Barber
STSimon G Thompson
Simon G Thompson
Objective To review critically the statistical methods used for health economic evaluations in randomised controlled trials where an estimate of cost is available for each patient in the study. Design Survey of published randomised trials including an economic evaluation with cost values suitable for statistical analysis; 45 such trials published in 1995 were identified from Medline. Main outcome measures The use of statistical methods for cost data was assessed interms of the descriptive statistics reported, use of statistical inference, and whether the reported conclusions were justified. Results Although all 45 trials reviewed apparently had cost data for each patient, only 9 (20%) reported adequate measures of variability for these data and only 25 (56%) gave results of statistical tests or a measure of precision for the comparison of costs between the randomised groups. Only 16 (36%) of the articles gave conclusions which were justified on the basis of results presented in the paper. No paper reported sample size calculations for costs Conclusions The analysis and interpretation of cost data from published trials reveal a lack of statistical awareness. Strong and potentially misleading conclusions about the relative costs of alternative therapies have often been reported in the absence of supporting statistical evidence. Improvements in the analysis and reporting of health economic assessments are urgently required. Health economic guidelines need to be revised to incorporate more detailed statistical advice.